Date: Thu, 18 Dec 1997 17:52:05 GMT Server: Apache/1.2.4 Last-Modified: Thu, 30 Oct 1997 19:29:45 GMT ETag: "9a5a-1714-3458e029" Content-Length: 5908 Accept-Ranges: bytes Connection: close Content-Type: text/html Scientific Advisory Board

Avigen Scientific Advisory Board

Gary J. Kurtzman, M.D., is Chairman of the Scientific Advisory Board. Dr. Kurtzman serves as Vice President, Research and Development for the Company. "See Management, Directors and Executive Officers."

Jef D. Boeke, Ph.D., co-invented capsid targeted viral inactivation technology that provides a basis for Avigen's infectious disease product development program. Dr. Boeke is a professor of Molecular Biology and Genetics at The Johns Hopkins University School of Medicine and has authored more than 100 publications.

Jerome E. Groopman, M.D. serves as chief of Hematology/Oncology at Harvard University's New England Deaconess Hospital in Boston and holds the Dina and Raphael Recantati Chair at Harvard Medical School. In addition, Dr. Groopman serves on the Board of Directors of the American Foundation for AIDS Research and is a member of the FDA Biological Response Modifiers Advisory Committee.

Mark A. Israel, M.D., is Professor of Neurological Surgery and Pediatrics and Director, The Preuss Laboratory of Molecular Neuro-oncology at the University of California, San Francisco. Prior to that, Dr. Israel was Head, Molecular Genetics Section in the Pediatric Branch of the National Cancer Institute. Dr. Israel’s research has focused on the molecular and cellular biology of tumors of the nervous system and has authored more than 150 publications. In addition, he has received numerous honors for his work in this field and is a member of the editorial boards of a number of scientific journals.

Yuichi Iwaki, M.D., Ph.D. serves as a director of the Company. "See Management — Directors and Executive Officers."

Y.W. Kan, M.D., D.Sc. is the Louis K. Diamond Professor of Hematology at the University of California at San Francisco. He also is an Investigator of the Howard Hughes Medical Institute. Dr. Kan was the 1991 recipient of the Albert Lasker Clinical Medical Research Award and is noted as a leader in the fields of sickle cell anemia and thalassemia.

Keiya Ozawa, M.D., Ph.D. is a professor of Molecular Biology, Institute of Hematology, at Jichi Medical School in Japan, where he has established a research and preclinical program in gene therapy. Dr. Ozawa is regarded as one of the leading authorities on gene therapy in Japan and is responsible for drafting the Japanese government's gene therapy guidelines. Dr. Ozawa holds both a M.D. and a Ph.D. from the University of Tokyo and is the author of more than 90 publications regarding virology, hematology and gene therapy.

Jeffrey M. Rosen, Ph.D. is a professor of Cell Biology at Baylor College of Medicine. Dr. Rosen is an internationally recognized expert in the field of gene expression. His research has focused primarily on the mechanisms of tissue-specific gene expression in the mammary and prostate glands. Dr. Rosen has served on the editorial board of the Journal of Biological Chemistry, Molecular and Cellular Endocrinology, Molecular Endocrinology and as executive editor of Nucleic Acids Research.


HomePageWhatsNewAAV VectorsNasdaq-AVGNEmploymentCorporate PartnersTable of Contents